Abstract
Introduction

Amyloid-␤ (A␤) peptide generation and aggregation as plaques are key pathological events in the development of Alzheimer's disease (AD)
. A␤ peptides and plaques have been extensively studied and evidenced to be neurotoxic, as they are reported mediators of apoptosis [6, 7] , inflammation [8, 9] and oxidative stress [10, 11] . For this reason, some of the earliest proposed therapeutic strategies entail the prevention or elimination of these A␤ peptides and subsequent deposits. A␤ peptides are produced via the amyloidogenic pathway of amyloid precursor protein (APP) proteolysis, which involves the concerted effort of ␤ and ␥-secretases [5, 12] [16, 17] . While both cleavage events are essential to the formation of the peptide, it is the ␥-secretase cleavage that determines which of the two major forms of the peptide (A␤1- 40, 42) will be generated and consequently both the peptide's ability to aggregate and the rate at which it is deposited [18, 19] . Thus, one clear potential therapeutic target for AD has been ␥-secretase. [20, 21] . In addition to previous reports that novel ␥-secretase inhibitors (GSI) significantly reduced A␤ production both in vitro and in vivo [22] [23] [24] [25] [26] 279/216 ), phospho-GSK-3␤ (Ser 9 ) and total GSK-3␣/␤ were purchased from Sigma. A␤1-40, 42 (20 mM Tris, pH 7.5, 150 mM NaCl, 1mM EDTA, 1 mM EGTA, 1% v/v Triton X-100, 2.5 mM sodium pyropgosphate, 1 mM ␤-glycerolphosphate, 1 mM Na3VO4, 1 g/ml leupeptin, 1 mM PMSF) as previously described [41] . Mouse [41] . These mice were then sacrificed at 9 months of age for analyses of A␤ levels and A␤ load in the brain according to previously described methods [44] Fig. 1B 
. Initially, ␤-secretase (BACE) cleaves APP, creating an A␤-containing carboxyl-terminal fragment known as ␤-C-terminal fragment (␤-CTF), or C99 [13-15]. This proteolysis also generates an amino-terminal, soluble APP-␤ (sAPP-␤) fragment, which is released extracellularly. Intracellularly, ␤-CTF is then cleaved by a multi-protein ␥-secretase complex that results in generation of the A␤ peptide and a smaller ␥-CTF, also known as C57
Despite the potential toxicity involving possible disruption of Notch signalling and intracellular accumulation of ␤-CTFs, ␥-secretase inhibition remains a viable anti-amyloidogenic strategy
Western blot and immunoprecipitation
Cultured cells were lysed in ice-cold-lysis buffer
and D, Western blot analysis shows a concentration-dependent accumulation of both ␣ and ␤ CTFs, approximately two-to three-fold increases in either cell line. Given the obvious implications on ␥-secretase activity, we analysed what effect luteolin treatment had on SweAPP N2a cells using a fluorometric assay for ␥-cleavage. In accordance with expectations, luteolin lowered ␥-secretase cleavage activity in both a concentration and time-dependent fashion (Fig. 1E and F). More importantly, these concentration and time-dependent decreases in ␥-secretase cleavage activity correlate with the decreases in total A␤ generation (Fig. 1E and F).
Taken together, the above data suggest that luteolin exerts its anti-amyloidogenic effects through down-regulation of ␥-secretase activity.
Luteolin reduces GSK-3␣/␤ activation in SweAPP N2a cells and Tg2576 mouse-derived primary neuronal cells
To establish the mechanism whereby luteolin modulates ␥-secretase activity and subsequent A␤ generation, we evaluated the effect this compound had on a variety of proteins related to and/or required for proper functioning of the ␥-secretase complex. Interestingly, we found that luteolin (20 M) increased levels of serine 21 phosphorylated inactive GSK-3␣ isoforms in both SweAPP N2a and primary Tg2576-derived neuronal cells (Fig. 2) . However, we did not observe any significant changes in overall expression of either GSK3-␣ or ␤ by Western blot, confirming that this phenomenon most likely occurs at the post-translational or protein stage of this kinase (Fig. 2) . In addition, this increase in GSK-3␣ serine 21 residue phosphorylation-mediated inactivation continued through 3 hrs (Fig. 2B and E) . At the same time, it is evident that levels of tyrosine 279 phosphorylated active GSK-3␣ isoforms decreased in time-dependent manner ( Fig. 2B and E) 
GSK-3 inhibition alters PS1 processing/phosphorylation in SweAPP N2a cells
As indicated by Fig. 3A-C (Fig. 4A) Fig.  6E . Finally, to assess this potential decrease, we conducted ELISA of both soluble and insoluble A␤1-40, 42 (Fig. 6F) . Luteolin treatment markedly reduced both soluble isoforms of A␤ by 25% and 49%, respectively (Fig. 6F) . However, we found no such significant reductions in insoluble A␤ isoforms (Fig. 6F) 
SB-415286 treatment
Western blot analysis using antiactin antibody shows actin protein (as an internal reference control). Densitometry analysis shows the ratio of phospho-GSK-3␣ (Ser
) to total GSK-3␣ as indicated below the figures (n = 3 for each condition). (A, D) One-way ANOVA followed by post hoc comparison revealed a significant difference between 0 min. and 5, 10, 15, 20 or 25 min. (P < 0.001). For (B, E), Western blot analysis using anti-phospho-GSK-3␣/␤(Tye 279/216 ) antibody shows two bands (51 and 47 kD) corresponding to phosphorylated forms of GSK-3␣ and GSK-3␤ or using anti-phospho-GSK-3␤ (Ser 9 ) antibody recognizes phosphorylated form of GSK-3␤ at 47 kD. Anti-actin antibody was used as shows an internal reference control. Densitometry analysis shows the ratio of phospho-GSK-3␣ (Tye 279/216 ) to total GSK-3␣ as indicated below the figures (n = 3 for each condition). (B, E)
GSK-3␣ regulates PS1-APP association in SweAPP N2a cells
Although previous study has linked GSK-3 inhibitors to reduced A␤ generation through the ␥-secretase complex [37], the manner in which this complex's activity is affected remains unclear. To clarify how phospho-PS1 CTF isoforms may regulate ␥-secretase activity, cell lysates of treated SweAPP N2a cells were immunoprecipitated by PS1 antibody and probed for APP (Fig. 5). As illustrated in Fig. 5A, the APP-PS1 association is significantly disrupted by not only luteolin and SB-415286 treatment, but also by GSK-3␣ siRNA. Moreover, this treatment-mediated disruption has no correlation to full-length APP levels (Fig. 5B). This analysis suggests that treatment has little effect on APP expression/trafficking. Thus, it is likely that GSK-3␣ or, more specifically, downstream phosphorylation of the PS1 CTF plays an essential role in regulating the association of ␥-secretase complex with its APP substrate.
Luteolin reduces GSK-3 activation and results in reduction of cerebral A␤ levels in Tg2576 mice
To validate the above findings in vivo, we treated 8 month-old Tg2576 mice with 20 mg/kg luteolin administered by daily intraperitoneal injection for 30 days. Brain homogenates from these mice were subsequently analysed by immunoprecipitation, Western blot and ELISA (Fig. 6). As shown in Fig. 6A, both GSK-3␣/␤ active isoforms from the homogenates of luteolin treated mice are reduced when compared to control. Moreover, ratios of each phosphorylated GSK-3 isoform to its respective holo protein revealed a significant decrease in activation with treatment (P < 0.001, Fig. 6A). These decreases in activation are also apparent in the immunohistochemical analysis of GSK-3␣/␤ activity in neurons of the CA1 region of the hippocampus and regions of the cingulate cortex (Fig. 6C). Western blot analysis of PS1 from treated mice interestingly shows significantly lower levels of PS1 processing by CTF to actin ratios (P < 0.001, Fig. 6B). To further confirm our mechanism in this model, brain homogenates were immunoprecipitated by PS1 antibody and probed for APP. As expected, luteolin treatment effectively abolished the PS1-APP association (Fig. 6D). We also observed no significant changes in
Fig. 3 PS1 phosphorylation is associated with luteolin-mediated inhibition of A␤ generation. SweAPP N2a cells were treated with luteolin at a range of concentrations for 4 hrs or at 20 M for various time-points as indicated. Cell lysates were prepared from these cells and subjected to Western blot analyses of PS1 C-terminal fragments (CTF) (A) and N-terminal fragment (NTF) (C). Western blot analysis by anti-PS1 CTF antibody shows two bands corresponding to phosphorylated PS1 CTF (p-CTF) and one dephosphorylated PS1 CTF (CTF). While Western blot analysis by anti-PS1 CTF antibody shows tow bands corresponding to holo PS1 and PS1 NTF. For (B), cell lysates from luteolin treated cells (20 M) were incubated with calf-intestine alkaline phosphatase (CIAP) or buffer for various time-points. Western blot analysis by anti-PS1 CTF antibody confirms two higher molecular weight bands corresponding to phosphorylated isoforms. Densitometry analysis shows the ratio of PS1 p-CTF to CTF below figures. A t-test revealed a significant deference between luteolin concentrations and time-points for ratio of PS1 p-CTF to CTF (P < 0.005 with n = 3 for each condition, but not for ratio of holo PS1 to PS1 NTF (P > 0.05 with n = 3 for each condition) at each time-point examined. Cultured media were collected for A␤ ELISA. Data correspond to percentage of A␤1-40, 42 peptides secreted 4 hrs after luteolin treatment relative to control (untreated) as indicated below panel (A). holo APP expression following treatment and even detected a potential decrease in oligomeric forms of A␤ as illustrated in
Oral administration of diosmin reduces A␤ pathology in Tg2576 mice
Previous pharmacokinetic studies suggest luteolin has an oral bioavailability <2% and a half-life in plasma <4 hrs, which would make it a poor candidate compound for oral clinical trials [45, 46] . [47] . [28, 37, 48, 49] (Fig. 4) . Moreover, both in vitro and in vivo analyses reveal significant reductions in APP co-immunoprecipitated with PS1 following treatment (Figs. 5A, B and 6D, E) . Accordingly, we would expect the concentration and time-dependent reductions in A␤1-40, 42 generation following treatment that we observe in Fig. 1E and F. Even though it is apparent that ␥-secretase activity also dose-and time-dependently decreases ( Fig. 1E and F [51, 52] . What is more, the presence of these aforementioned phosphorylated PS1 CTFs corresponded with both reduction of A␤ generation and accumulation of the ␤-CTF of APP [51] [52] [53] , which is what we clearly observe following luteolin treatment (Fig. 1) [59, 60] , anti-inflammatory agent [61, 62] and immunomodulator [63, 64] , possibly owing these two latter properties to its GSK-3 inhibitory nature. However, it must be noted that although we observe changes consistent with GSK-3 inhibition following luteolin treatment, it remains unclear whether or not this flavonoid is a direct inhibitor of this kinase. What seems to be evident, and a point at which it potentially differs from direct GSK-3 inhibitors (including SB-415286), is that luteolin treatment appears to selectively inactivate GSK-3␣ isoforms over ␤ isoforms (Fig. 2) . That is to say, luteolin treatment does appear to reduce active GSK-3␤ isoforms expressed at about 2 hrs (Fig. 2B and E) , as compared to control (data not shown), but expression of active GSK-3␣ isoforms is more timely and effectively reduced (Fig. 2B and E) . Remarkably, we also find that ␤-catenin remains unaffected by luteolin treatment, which may imply that this selective GSK-3 inactivation can circumvent the potential toxicity of more general Fig. 2C and F) following treatment, which suggests that luteolin may affect the positive feedback loop of GSK-3 activation by inactivating the PP1 phosphatase [65] . The direct targeting of this feedback loop as a means to reduce GSK-3 activation seems highly probable in light of the fact that calyculin A, a PP1 inhibitor, treatment has previously been found to increase PS1 CTF phosphorylation [52] .
Taking this situation into consideration, we screened other compounds with a 5,7-dihydroxyflavone structural backbone to identify a more suitable flavonoid for oral administration (Fig. 7). One compound, diosmetin, proved to be just as efficacious as luteolin in promoting PS1 CTF phosphorylation and consequently inhibiting ␥-secretase activity in SweAPP N2a cells (data not shown). Cova et al. reported that the flavonoid diosmin, a well-evidenced vascular protecting agent, is rapidly transformed by intestinal flora to its aglycone form, diosmetin. Taken in this manner, diosmetin was found to be readily absorbed and rapidly distributed throughout the body with a plasma half-life >26 hrs
Fig. 4 GSK-3␣ regulates PS1 phosphorylation. For (A), SweAPP N2a cells were treated with a known GSK-3 inhibitor (SB-415286) at 20 M for various time-points. Western blot analysis by anti-PS1 CTF antibody produces a similar phosphorylation profile to that of luteolin-treated cells. Densitometry analysis shows the ratio of PS1 p-CTF to CTF and ratio of holo PS1 to actin as indicated below the figures. A t-test revealed significant differences between time-points for the ratio of PS1 p-CTF to CTF (P < 0.001 with n = 3 for each condition). For (B), expression of PS1 C-terminal fragments was analysed by Western blot in cell lysates from SweAPP N2a cells transfected with siRNA targeting GSK-3␣, ␤, or mock transfected 48 hrs after transfecion. Prior to experiments, siRNA knockdown efficiency >70% for GSK-3␣, ␤ was confirmed by Western blot analysis (data not shown). Densitometric analysis reveals the ratio of PS1 p-CTF to CTF as indicated below the each panel. A t-test revealed significant differences between GSK-3␣ siRNA-transfected cells and GSK-3␤ siRNA or control (Mock transfected cells) (P < 0.001 with n = 4 for each condition) on the ratio of PS1 p-CTF to CTF. In addition, a t-test also revealed significant differences between luteolin-treated cells and GSK-3␤ siRNA or control (Mock transfeced cells) (P < 0.001 with n = 4 for each condition) on the ratio of PS1 p-CTF to CTF.
Discussion
Although previous reports have substantiated the therapeutic potential of GSK-3 inhibitors in AD
GSK-3 inhibitors (data not shown). Furthermore, there is a clear correlation between increases in inactive and decreases in active GSK-3␣ (
Turning to luteolin's efficacy as an anti-amyloidogenic agent, we find that luteolin treatment markedly reduces both soluble A␤1-40, 42 isoforms in vivo (Fig. 6F) . Even though we observe no significant changes in insoluble A␤1-40, 42 isoforms (Fig. 6F) , one would expect this result given the age and consequent low plaque burden of these Tg2576 mice [43] . Like many aglycone forms of flavonoids, luteolin potentially reaches its molecular target by passive diffusion through cell membranes. This means of cellular uptake may explain the rapid onset of GSK-3␣ inactivation as we observed following luteolin treatment ( Fig. 2A and D 
